SIGLEC1 and melanoma: Several studies have reported a correlation between CD169+ macrophages and CD8+ T cell infiltration, improving overall survival rates in cancers, such as colorectal cancer, malignant melanoma, endometrial carcinoma, breast cancer and bladder cancer [48–52].